Ivantis cleared to begin trial of Hydrus in advanced glaucoma

The FDA has cleared Ivantis to begin a second investigational device exemption clinical trial for its Hydrus microstent, according to a company press release.The clearance will allow the company to study the microstent in patients with advanced glaucoma who are undergoing standalone glaucoma surgery without combined cataract surgery.